Also, two recommendations were deleted from original ESMO; “use of preoperative chemotherapy for IB‐III GC” and “use of embrolizumab for patients with adenocarcinoma of the esophagus and esophago‐gastric junction expressing PD‐L1 CPS ≥1.” Therefore, Pan‐Asian authors achieved a 100% consensus on the “acceptability” of ESMO recommendations. This evidence concerns the gene CD274 and adenocarcinoma.